ATE91392T1 - Formulierung zur behandlung der nierenkrankheiten. - Google Patents

Formulierung zur behandlung der nierenkrankheiten.

Info

Publication number
ATE91392T1
ATE91392T1 AT90111519T AT90111519T ATE91392T1 AT E91392 T1 ATE91392 T1 AT E91392T1 AT 90111519 T AT90111519 T AT 90111519T AT 90111519 T AT90111519 T AT 90111519T AT E91392 T1 ATE91392 T1 AT E91392T1
Authority
AT
Austria
Prior art keywords
treatment
formulation
composition
amino acids
mixtures
Prior art date
Application number
AT90111519T
Other languages
English (en)
Inventor
Pamela Ann Anderson
Tivadar Gabor Mohacsi
Kent Lee Cipollo
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23454347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE91392(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE91392T1 publication Critical patent/ATE91392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90111519T 1989-06-21 1990-06-19 Formulierung zur behandlung der nierenkrankheiten. ATE91392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/369,163 US4957938A (en) 1989-06-21 1989-06-21 Nutritional formulation for the treatment of renal disease
EP90111519A EP0405295B1 (de) 1989-06-21 1990-06-19 Formulierung zur Behandlung der Nierenkrankheiten

Publications (1)

Publication Number Publication Date
ATE91392T1 true ATE91392T1 (de) 1993-07-15

Family

ID=23454347

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90111519T ATE91392T1 (de) 1989-06-21 1990-06-19 Formulierung zur behandlung der nierenkrankheiten.

Country Status (9)

Country Link
US (1) US4957938A (de)
EP (1) EP0405295B1 (de)
JP (1) JPH0331211A (de)
KR (1) KR910000140A (de)
AT (1) ATE91392T1 (de)
AU (1) AU627041B2 (de)
CA (1) CA2019472A1 (de)
DE (1) DE69002201T2 (de)
ES (1) ES2058687T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
EP0663826B1 (de) * 1991-09-27 1998-12-23 Board Of Regents The University Of Texas System Parenteral anzuwendende Aminosäuren enthaltende Zubereitungen zur Bekämpfung von Hypotension und verwandten Pathologien
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
DE69530067T2 (de) * 1994-10-07 2004-01-29 Firmenich & Cie Aromazusammensetzungen und aromatisierungsverfahren
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
FR2775901B1 (fr) * 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
US6288116B1 (en) 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
US6605115B1 (en) * 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US7696219B2 (en) * 2000-09-27 2010-04-13 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiences in renal patients
US6995166B1 (en) 2000-09-27 2006-02-07 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiencies in renal patients
US6989164B2 (en) * 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
FR2822704B1 (fr) * 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
WO2002081020A2 (en) * 2001-04-04 2002-10-17 Critical Therapeutics, Inc. Method for preventing acute renal failure
ITTO20020672A1 (it) * 2002-07-26 2004-01-26 Medestea Res And Production S Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale
AU2005218539A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
ES2882278T3 (es) * 2018-07-31 2021-12-01 Evonik Operations Gmbh Mezclas de cetoácidos de cadena ramificada (BCKA) y procedimiento para la producción de tales mezclas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
GB1511302A (en) * 1974-04-15 1978-05-17 Univ Johns Hopkins Pharmaceutical compositions comprising amino acid analogues
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4677121A (en) * 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4752619A (en) * 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia
FR2615734B1 (fr) * 1987-05-27 1989-12-01 Synthelabo Compositions pharmaceutiques contenant un melange de sels de cetoacides et d'amino-acides utiles pour le traitement de l'uremie

Also Published As

Publication number Publication date
EP0405295A2 (de) 1991-01-02
KR910000140A (ko) 1991-01-29
EP0405295A3 (en) 1991-03-27
DE69002201D1 (de) 1993-08-19
US4957938A (en) 1990-09-18
EP0405295B1 (de) 1993-07-14
AU627041B2 (en) 1992-08-13
CA2019472A1 (en) 1990-12-21
AU5767390A (en) 1991-01-03
DE69002201T2 (de) 1994-01-05
ES2058687T3 (es) 1994-11-01
JPH0331211A (ja) 1991-02-12

Similar Documents

Publication Publication Date Title
ATE91392T1 (de) Formulierung zur behandlung der nierenkrankheiten.
DE69305105D1 (de) Zusammensetzungen zur oralen Nahrungsmittelaufnahme mit verbessertem Geschmack
DE69627748D1 (de) Zusammensetzung zur Behandlung von Nierenversagen
JPS56110617A (en) Nutrient composition for young child
FI904074A7 (fi) Optimoidun aminohappokoostumuksen omaavat proteiini-, peptidi- ja aminohapposeokset sekä niiden käyttö keskosten ja rintalasten ravinnon sekä äidinmaidon lisäaineiden valmistamiseksi
ATE113441T1 (de) Proteinhydrolysaten.
IL162244A (en) Infant formula compositions comprising increased amounts of alpha-lactalbumin
ES2066335T5 (es) Dispersiones de proteinas en productos alimentarios.
SE8505048D0 (sv) Nutritionsemulsion med syretransporterande egenskaper
NO865217D0 (no) Fremgangsmaate for fremstilling av anti-uremiapreparater.
CA2326148A1 (en) Method for providing glutamine
ATE69164T1 (de) Arzneimittel zur behandlung von uraemie.
FR2556593B1 (fr) Composition nutritive contenant de l'acide alpha-cetoisocaproique, de la leucine et des acides amines essentiels et non essentiels
Possompes et al. Factors affecting the evaluation of the nutritional value of severely alkali-treated casein
EP1407677A3 (de) Teilhydrolysierte Fischgelatine enthaltende Zubereitungen und deren Verwendung
JPS5533446A (en) Amino acid transfusion for postoperative patient
Diehl et al. Vitamin E deficiency in rabbits receiving a high PUFA diet with and without a non-absorbable antioxidant II. Incorporation of14C-labelled glycine andl-leucine into liver and plasma proteins
DE3676926D1 (de) Carbonsaeuresalze und methode zum aromatisieren von lebensmitteln und tabak.
SE8404715D0 (sv) Farmaceutisk komposition och metod for behandling av psykomotorisk spenning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
RZN Patent revoked